United States securities and exchange commission logo May 10, 2022 Matthew Hidalgo Chief Financial Officer VISION HYDROGEN Corp 95 Christopher Columbus Drive, 16th Floor Jersey City, New Jersey 07302 Re: VISION HYDROGEN Corp Form 10-K for the Fiscal Year Ended December 31, 2021 Filed April 15, 2022 File No. 000-55802 Dear Mr. Hidalgo: We have limited our review of your filing to the financial statements and related disclosures and have the following comment. In our comment, we may ask you to provide us with information so we may better understand your disclosure. Please respond to this comment within ten business days by providing the requested information or advise us as soon as possible when you will respond. If you do not believe our comment applies to your facts and circumstances, please tell us why in your response. After reviewing your response to this comment, we may have additional comments. Form 10-K for The Year Ended December 31, 2021 Financial Statements Note 17. Business Acquisition, page F-20 1. We reference your disclosure that the VoltH2 acquisition was accounted for as an asset acquisition with no step up basis due to the 15.9% ownership of VoltH2 by Vision Hydrogen prior to the acquisition. Please explain to us what assets were acquired and how you accounted for those assets in accordance with ASC 805. Clarify your basis in the accounting literature for recording a deemed dividend in this transaction. In addition, explain to us why you believe there is common control between the entities. Matthew Hidalgo VISION HYDROGEN Corp May 10, 2022 Page 2 In closing, we remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. You may contact Jeanne Bennett at 202-551-3606 or Julie Sherman, Senior Accountant, at 202-551-3640 with any questions. FirstName LastNameMatthew Hidalgo Sincerely, Comapany NameVISION HYDROGEN Corp Division of Corporation Finance May 10, 2022 Page 2 Office of Life Sciences FirstName LastName